Swanson Mark S, Hudson Rachael L, Bhandari Nipun, Sinha Uttam K, Maceri Dennis R, Kokot Niels
Department of Otolaryngology-Head and Neck Surgery, University of Southern California, Los Angeles.
Keck School of Medicine, University of Southern California, Los Angeles, California.
JAMA Otolaryngol Head Neck Surg. 2015 Aug;141(8):723-7. doi: 10.1001/jamaoto.2015.1176.
Chyle fistula is an uncommon complication of neck surgery. A variety of management strategies have been described, including diet restriction, parenteral nutrition, use of pressure dressings, and revision surgery. Octreotide has been used with success in patients with neck and thoracic chyle fistulas, but data regarding efficacy in neck chyle fistulas are lacking.
To evaluate the efficacy of octreotide for use in patients with postoperative chyle fistulas.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective review of 12 patients who received octreotide for neck chylous fistula after neck dissection was performed during the period 2004 through 2014 at 2 tertiary care academic hospitals.
Patients with postoperative neck chyle fistulas were given a restricted diet and subcutaneous octreotide.
The main outcome was fistula closure rate, defined as fistula resolution without surgical intervention. Secondary outcomes of fistula duration (days from detection until resolution), length of hospital stay (surgery to discharge), and treatment complications were also examined.
All 12 patients had resolution of their neck chyle fistula with octreotide therapy without need for revision surgery. Mean (SD) hospital stay was 8.7 (4.76) days, with a range of 3 to 18 days. The chyle fistula resolved after a mean (range) 5.5 (2-11) days. Self-resolving nausea was encountered in 1 patient from octreotide use, and 1 patient developed a salivary fistula as a result of the chylous fistula.
In these patients, octreotide was safe and effective in resolving neck chylous fistulas. Octreotide therapy appears superior to traditional conservative measures of diet restriction and pressure dressings when compared with literature rates. A prospective study is needed to confirm results, but octreotide therapy should be considered as first-line conservative management for neck chyle fistulas that occur after neck surgery.
乳糜瘘是颈部手术罕见的并发症。已描述了多种管理策略,包括饮食限制、肠外营养、使用压力敷料和修复手术。奥曲肽已成功用于治疗颈部和胸部乳糜瘘患者,但缺乏关于其对颈部乳糜瘘疗效的数据。
评估奥曲肽用于术后乳糜瘘患者的疗效。
设计、地点和参与者:对2004年至2014年期间在2家三级医疗学术医院接受颈部清扫术后因颈部乳糜瘘接受奥曲肽治疗的12例患者进行回顾性研究。
术后颈部乳糜瘘患者接受饮食限制和皮下注射奥曲肽。
主要结局为瘘管闭合率,定义为无需手术干预即可使瘘管消退。还检查了瘘管持续时间(从发现到消退的天数)、住院时间(手术至出院)和治疗并发症等次要结局。
所有12例患者经奥曲肽治疗后颈部乳糜瘘均消退,无需进行修复手术。平均(标准差)住院时间为8.7(4.76)天,范围为3至18天。乳糜瘘平均(范围)在5.5(2 - 11)天后消退。1例患者因使用奥曲肽出现自限性恶心,1例患者因乳糜瘘并发唾液瘘。
在这些患者中,奥曲肽在解决颈部乳糜瘘方面安全有效。与文献报道的发生率相比,奥曲肽治疗似乎优于传统的饮食限制和压力敷料等保守措施。需要进行前瞻性研究以证实结果,但奥曲肽治疗应被视为颈部手术后发生的颈部乳糜瘘的一线保守治疗方法。